Eledon Pharmaceuticals Inc
eledon.comWhat Do They Do?
Develops tegoprubart, an immune-system drug for people receiving organ transplants and people with ALS.
10-K for FY2025, filed Mar 19, 2026
How Do They Make Money?
No revenue reported yet.
10-K, filed Mar 3, 2017
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$31.6MView ↗
- ▲ +182% (Loss)
- vs −$11.2M in Q2 FY2025
Narrower development focus
The earlier report described tegoprubart development for kidney and islet transplants, IgAN and ALS; the latest prioritizes kidney transplantation, discontinues the company-funded islet and IgAN programs, and says ALS development needs additional financing.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 19, 2026Our business strategy is to optimize the clinical and commercial value of tegoprubart and become a global biopharmaceutical company with a…View ↗
Our business strategy is to optimize the clinical and commercial value of tegoprubart and become a global biopharmaceutical company with a…View ↗
Loading...
